We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+16.53%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.77B
AUM Growth
+$173M
Cap. Flow
+$55.4M
Cap. Flow %
3.14%
Top 10 Hldgs %
80.46%
Holding
31
New
5
Increased
4
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$100M
2
BLUE
bluebird bio
BLUE
+$20.5M
3
SVRA icon
Savara
SVRA
+$11.1M
4
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$10.2M
5
ARYD
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
+$7.56M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$114M

Sector Composition

Rank Sector Weight
1 Healthcare 92.43%
2 Financials 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
26
Tango Therapeutics
TNGX
$4.31B
$5.56M 0.32%
500,000
– –
BLSA
27
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.15M 0.29%
487,500
– –
OMEG
28
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$3.96M 0.22%
+400,000
New +$4.15M
FLACU
29
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$3.05M 0.17%
300,000
– –
JYAC
30
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.95M 0.17%
300,000
– –
MLTX icon
31
MoonLake Immunotherapeutics
MLTX
$1.47B
$2.55M 0.14%
250,000
– –
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q1 2021 Portfolio in Review

As of Q1 2021, Bain Capital Life Sciences Investors held 31 positions worth $1.77B, up 11% from $1.59B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Bain Capital Life Sciences Investors deployed $55.4M of net new capital in Q1 2021, opening 5 new positions and adding to 4 existing holdings. Its largest new stake was Pharvaris: 3,180,601 shares worth $89M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $114M trimmed.

  • Bain Capital Life Sciences Investors's largest Q1 2021 buy was Pharvaris: 3,180,601 shares worth $89M.
  • Bain Capital Life Sciences Investors added most to Savara in Q1 2021, an estimated $11.1M increase.
  • Bain Capital Life Sciences Investors's biggest Q1 2021 reduction was SpringWorks Therapeutics, cutting an estimated $114M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 80% of its $1.77B portfolio in Q1 2021.
  • Bain Capital Life Sciences Investors opened 5 new positions and closed 0 in Q1 2021.
  • Bain Capital Life Sciences Investors's portfolio value rose 11% quarter-over-quarter to $1.77B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2021, filed 17 May 2021.